LO ÚLTIMO EN ANTIDEPRESIVOS [genotipos de citocromos] ► Genomics|Features|Pharmacogenomics [idioma inglés únicamente]

Genomics|Features|Pharmacogenomics

Pharmacogenomics

Antidepressants, Pharmacogenomics and Public Health - February 23, 2015

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
Hicks J K et al. Clin. Pharmacol. Ther. 2013 May (5) 402-8

CPIC dosing guideline for amitriptyline and CYP2C19, CYP2D6
The CPIC Dosing Guideline for amitriptyline recommends an alternative drug for CYP2D6 or CYP2C19 ultrarapid metabolizers and for CYP2D6 poor metabolizers. Consider a 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 intermediate metabolizers, 2013

Pharmacogenomic testing for dose adjustment of selected antidepressants
CDC Tier-2 classification (under psychiatry)

Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar C A et al. Pharmacogenomics J. 2015 Feb 17.

Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study.
Noordam Raymond et al. J Psychiatr Res 2015 Jan 20.

Genetic determinants of selective serotonin reuptake inhibitor related sexual dysfunction.
Stevenson James M et al. Pharmacogenomics 2014 Nov (14) 1791-1806

Genetic prediction of antidepressant drug response and nonresponse in Korean patients.
Lim Shinn-Won et al. PLoS ONE 2014 (9) e107098

Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans.
Wong Ma-Li et al. Am J Psychiatry 2014 Sep 15.

Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians.
Zai Gwyneth et al. Pharmacogenomics 2014 Jun (8) 1147-57

Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.
Fabbri Chiara et al. Expert Opin Drug Metab Toxicol 2014 Aug (8) 1093-118

From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.
Fabbri Chiara et al. Can J Psychiatry 2014 Feb (2) 62-75

Is there a role for antidepressant and antipsychotic pharmacogenetics in clinical practice in 2014?
Mulsant Benoit H et al. Can J Psychiatry 2014 Feb (2) 59-61

Check out genes and genomewide association studies reported in relation to antidepressant use and outcomes, from the HUGE Navigator

Check out genetic tests related to selective serotonin reuptake inhibitor toxicity, from the NIH Genetic Testing Registry

Clopidogrel, Pharmacogenomics and Drug Therapy: Where Are We? - February 9, 2015

CDC classsification of clopidogrel use in heart conditions as tier 2 (insufficient evidence-for use with informed decision

CYP2C19/clopidogrel

non-ST-segment elevation acute coronary syndrome, ST-elevation myocardial infarction, myocardial infarction, stroke, peripheral arterial disease

PGx

FDA-PGx Drug Information(2013) CPIC (2013) AHRQ

A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. 
Ruben L. Osnabrugge et al. Genetics in Medicine, June 19, 2014

Pilot study: incorporation of pharmacogenetic testing in medication therapy management services. 
Haga SB, et al. Pharmacogenomics. 2014 Nov;15(14):1729-1737.

CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. 
Sorich MJ, et al. Circ Cardiovasc Genet. 2014 Dec;7(6):895-902.

Clopidogrel: A multifaceted affair. 
Martínez-Quintana E, J Clin Pharmacol. 2015 Jan;55(1):1-9

Pharmacogenomic Testing in Practice: How Much Evidence Do We Need? - November 26, 2014

Evidence required to demonstrate clinical utility of pharmacogenetic testing: The debate continues. 
N K Gillis and F Innocenti. Clinical Pharmacology & Therapeutics (2014); 96 6, 655–657.

Useless until proven effective: The clinical utility of preemptive pharmacogenetic testing. 
A C J W Janssens and P A Deverka  Clinical Pharmacology & Therapeutics (2014); 96 6, 652–654.

Meaningful use of pharmacogenetics. 
M J Ratain and J A Johnson Clinical Pharmacology & Therapeutics (2014); 96 6, 650–652. 

Evidence-based Pharmacogenomic Testing: Where are we? - October 16, 2014

Editorial: A call for accurate pharmacogenetic labeling: Telling it like it is. 
Wylie Burke, et al. JAMA Internal Medicine, October 13, 2014 

Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels. 
Bo Wang, et al. JAMA Internal Medicine, October 13, 2014 

CDC information: How many pharmacogenomics tests have enough evidence to support their use in practice? Check out CDC table of genomic applications stratified by level of evidence

FDA table of pharmacogenomic markers

CDC paper:  Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.
Dotson W et al, Clin Pharmacol Ther. 2014 Apr;95(4):394-402.

CDC blog post: Medications for the masses? Why is pharmacogenomics a public health issue?

Pharmacogenomics: Gap Between Research and Practice - September 4, 2014

New study reveals pharmacogenomic  knowledge gaps among physicians, PharmGKB blog post, Aug 29

Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. 
Dickinson Barry, et al.  Pharmacogenomics and personalized medicine, July 2014

Implementation of personalized medicine services in community pharmacies: need for more education.  Alexander KM, et al. J Am Pharm Assoc (2003). 2014 Aug 22:e326-e333.

CDC information: How many pharmacogenomics tests have enough evidence to support their use in practice? Check out CDC evidence based table of genomic applications stratified by level of evidence

FDA table of pharmacogenomic markers

CDC paper:  Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Dotson W et al, Clin Pharmacol Ther. 2014 Apr;95(4):394-402.

CDC blog post: Medications for the masses? Why is pharmacogenomics a public health issue?